Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Importance of Continuing Education for Medical Staff to Improve the Confirmation Rate of Intent for Organ Donation.

Takahashi K, Wakasugi M, Okudera H, Seto C, Furuki I, Hasegawa T, Takahara S.

Transplant Proc. 2019 Dec;51(10):3213-3218. doi: 10.1016/j.transproceed.2019.08.043.

PMID:
31810504
2.

Electronic and Combustible Cigarette Use in Adolescence: Links With Adjustment, Delinquency, and Other Substance Use.

Staff J, Maggs JL, Seto C, Dillavou J, Vuolo M.

J Adolesc Health. 2020 Jan;66(1):39-47. doi: 10.1016/j.jadohealth.2019.08.030. Epub 2019 Nov 8.

PMID:
31711837
3.

Effectiveness of Synthetic Polymer-coated Peripherally Inserted Central Catheter in Patients With Advanced Cancer.

Takezawa Y, Izumi K, Kamijima T, Machioka K, Shima T, Iwamoto H, Nohara T, Shigehara K, Kadono Y, Seto C, Mizokami A.

In Vivo. 2019 May-Jun;33(3):877-880. doi: 10.21873/invivo.11553.

4.

Self-Assembly of Nanoparticles into Two-Dimensional Arrays for Catalytic Applications.

Yu C, Guo X, Muzzio M, Seto CT, Sun S.

Chemphyschem. 2019 Jan 7;20(1):23-30. doi: 10.1002/cphc.201800870. Epub 2018 Dec 27. Review.

PMID:
30444021
5.

Rational design of novel irreversible inhibitors for human arginase.

Guo X, Chen Y, Seto CT.

Bioorg Med Chem. 2018 Aug 7;26(14):3939-3946. doi: 10.1016/j.bmc.2018.06.015. Epub 2018 Jun 14.

PMID:
29914772
6.

Hydrodehalogenation of Polyhalogenated Aromatics Catalyzed by NiPd Nanoparticles Supported on Nitrogen-Doped Graphene.

Guo X, Yu C, Yin Z, Sun S, Seto CT.

ChemSusChem. 2018 May 25;11(10):1617-1620. doi: 10.1002/cssc.201800289. Epub 2018 Apr 20.

PMID:
29539207
7.

Maximizing the Catalytic Activity of Nanoparticles through Monolayer Assembly on Nitrogen-Doped Graphene.

Yu C, Guo X, Shen M, Shen B, Muzzio M, Yin Z, Li Q, Xi Z, Li J, Seto CT, Sun S.

Angew Chem Int Ed Engl. 2018 Jan 8;57(2):451-455. doi: 10.1002/anie.201709815. Epub 2017 Dec 7.

PMID:
29166555
8.

Evaluation of Factors Affecting Metastasis for Renal Cell Carcinoma Based on Current Guidelines in Japan.

Kadono Y, Kawaguchi S, Nohara T, Shigehara K, Narimoto K, Izumi K, Ikeda H, Yaegashi H, Miyagi T, Nakashima T, Seto C, Mizokami A.

Anticancer Res. 2017 Sep;37(9):5147-5153.

PMID:
28870947
9.

AgPd Nanoparticles Deposited on WO2.72 Nanorods as an Efficient Catalyst for One-Pot Conversion of Nitrophenol/Nitroacetophenone into Benzoxazole/Quinazoline.

Yu C, Guo X, Xi Z, Muzzio M, Yin Z, Shen B, Li J, Seto CT, Sun S.

J Am Chem Soc. 2017 Apr 26;139(16):5712-5715. doi: 10.1021/jacs.7b01983. Epub 2017 Apr 17.

PMID:
28402632
10.

Massive Ascites in a Renal Transplant Patient after Laparoscopic Fenestration of a Lymphocele.

Kawaguchi S, Nohara T, Shima T, Matsuyama S, Nose C, Yamahana J, Kadono Y, Seto C, Kawabata M, Mizokami A.

Case Rep Transplant. 2016;2016:7491627. Epub 2016 Nov 7.

11.

Usefulness of selective renal artery embolization for urinary fistula following partial nephrectomy: Two case reports.

Nohara T, Matsuyama S, Kawaguchi S, Miyagi T, Seto C, Mochizuki K.

Mol Clin Oncol. 2016 Jul;5(1):158-160. Epub 2016 May 4.

12.

Erratum to: Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility.

Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK.

Microbiome. 2016 Feb 22;4:10. doi: 10.1186/s40168-016-0158-1. No abstract available.

13.

Prostatic Stromal Tumor of Uncertain Malignant Potential Which Was Difficult to Diagnose.

Matsuyama S, Nohara T, Kawaguchi S, Seto C, Nakanishi Y, Uchiyama A, Ishizawa S.

Case Rep Urol. 2015;2015:879584. doi: 10.1155/2015/879584. Epub 2015 Dec 29.

14.

Holmium Laser Enucleation of the Prostate With Percutaneous Nephrostomy Into the Transplanted Kidney in Patient With Severe Benign Prostatic Hyperplasia With Vesicoureteral Reflux - A Case Report.

Nohara T, Matsuyama S, Shima T, Kawaguchi S, Seto C.

Urol Case Rep. 2015 Dec 10;4:33-5. doi: 10.1016/j.eucr.2015.11.003. eCollection 2016 Jan.

15.

Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility.

Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK.

Microbiome. 2014 Nov 25;2:42. doi: 10.1186/2049-2618-2-42. eCollection 2014. Erratum in: Microbiome. 2016;4:10.

16.

Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.

Kumada H, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S.

Hepatol Res. 2015 May;45(5):501-13. doi: 10.1111/hepr.12375. Epub 2014 Jul 29.

PMID:
24961662
17.

Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma.

Murphy SJ, Wigle DA, Lima JF, Harris FR, Johnson SH, Halling G, Asiedu MK, Seto CT, Terra S, Kosari F, Peikert T, Yang P, Aubry MC, Vasmatzis G.

Cancer Res. 2014 Jun 1;74(11):3157-67. doi: 10.1158/0008-5472.CAN-13-1727.

18.

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.

Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S.

J Hepatol. 2014 Aug;61(2):219-27. doi: 10.1016/j.jhep.2014.04.004. Epub 2014 Apr 12.

PMID:
24727123
19.

Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.

Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S.

J Gastroenterol. 2014 May;49(5):941-53. doi: 10.1007/s00535-014-0949-8. Epub 2014 Mar 14.

PMID:
24626851
20.

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.

Hayashi N, Seto C, Kato M, Komada Y, Goto S.

J Gastroenterol. 2014 Jan;49(1):138-47. doi: 10.1007/s00535-013-0875-1. Epub 2013 Sep 5.

21.

Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines.

Horan TC, Zompa MA, Seto CT, Kim KK, Moore RG, Lange TS.

Invest New Drugs. 2012 Aug;30(4):1460-70. doi: 10.1007/s10637-011-9728-z. Epub 2011 Aug 2.

PMID:
21809024
22.

The preparticipation physical examination: an update.

Seto CK.

Clin Sports Med. 2011 Jul;30(3):491-501. doi: 10.1016/j.csm.2011.03.008.

PMID:
21658544
23.

Reducing risk in basin scale CO2 sequestration: a framework for integrated monitoring design.

Seto CJ, McRae GJ.

Environ Sci Technol. 2011 Feb 1;45(3):845-59. doi: 10.1021/es102240w. Epub 2011 Jan 10.

PMID:
21218768
24.

Kinetic delay of cyclization/elimination-coupled enzyme assays: analysis and solution.

Xue F, Seto CT.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):1069-71. doi: 10.1016/j.bmcl.2010.09.104. Epub 2010 Sep 25.

PMID:
21211970
25.

Sensitivity and proportionality assessment of metabolites from microdose to high dose in rats using LC-MS/MS.

Ni J, Ouyang H, Seto C, Sakuma T, Ellis R, Rowe J, Acheampong A, Welty D, Szekely-Klepser G.

Bioanalysis. 2010 Mar;2(3):407-19. doi: 10.4155/bio.10.10.

PMID:
21083251
26.

A focused library of protein tyrosine phosphatase inhibitors.

Comeau AB, Critton DA, Page R, Seto CT.

J Med Chem. 2010 Sep 23;53(18):6768-72. doi: 10.1021/jm100528p.

PMID:
20731359
27.

Pediatric running injuries.

Seto CK, Statuta SM, Solari IL.

Clin Sports Med. 2010 Jul;29(3):499-511. doi: 10.1016/j.csm.2010.03.005.

PMID:
20610035
28.

The binding site of zinc and indium metal to amino acid derivatized squarate complexes - Implications in inhibitor and mediator designs.

Ramroop-Singh N, Narinesingh D, Singh G, Seto CT, Comeau AB.

Bioorg Chem. 2010 Oct;38(5):234-41. doi: 10.1016/j.bioorg.2010.06.001. Epub 2010 Jun 15.

PMID:
20598337
29.

Enantioselective synthesis of 1-aryltetrahydroisoquinolines.

Wang S, Onaran MB, Seto CT.

Org Lett. 2010 Jun 18;12(12):2690-3. doi: 10.1021/ol1004356.

PMID:
20481482
30.

Fluorogenic peptide substrates for serine and threonine phosphatases.

Xue F, Seto CT.

Org Lett. 2010 May 7;12(9):1936-9. doi: 10.1021/ol1003065.

PMID:
20359238
31.

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

Isabel E, Bateman KP, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Gauthier JY, Lamontagne S, Lau CK, Léger S, LeRiche T, Lévesque JF, Li CS, Massé F, McKay DJ, Mellon C, Nicoll-Griffith DA, Oballa RM, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):887-92. doi: 10.1016/j.bmcl.2009.12.083. Epub 2009 Dec 28.

PMID:
20061146
32.

Utility of follow-up of 131I-MIBG scintigraphy to screen pheochromocytoma.

Watanabe S, Kahara T, Seto C, Uchiyama A, Abo H, Ishikura K, Nakajima K, Usuda R.

Intern Med. 2009;48(18):1711-2. Epub 2009 Sep 15. No abstract available.

33.

Preparticipation cardiovascular screening in young athletes: current guidelines and dilemmas.

Seto CK, Pendleton ME.

Curr Sports Med Rep. 2009 Mar-Apr;8(2):59-64. doi: 10.1249/JSR.0b013e31819ccdaf.

PMID:
19276904
34.

Acute lumbar disk pain: navigating evaluation and treatment choices.

Gregory DS, Seto CK, Wortley GC, Shugart CM.

Am Fam Physician. 2008 Oct 1;78(7):835-42. Review.

35.

Macrocyclic inhibitors for the serine protease plasmin.

Xue F, Seto CT.

J Enzyme Inhib Med Chem. 2009 Jun;24(3):779-94. doi: 10.1080/14756360802364401.

PMID:
18825554
36.

Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry.

Ni J, Ouyang H, Aiello M, Seto C, Borbridge L, Sakuma T, Ellis R, Welty D, Acheampong A.

Pharm Res. 2008 Jul;25(7):1572-82. doi: 10.1007/s11095-008-9555-x. Epub 2008 Feb 26.

PMID:
18299965
37.

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. doi: 10.1016/j.bmcl.2007.12.047. Epub 2008 Jan 15.

PMID:
18226527
38.

Preclinical Cushing's syndrome resulting from adrenal black adenoma diagnosed with diabetic ketoacidosis.

Kahara T, Seto C, Uchiyama A, Usuda D, Akahori H, Tajika E, Miwa A, Usuda R, Suzuki T, Sasano H.

Endocr J. 2007 Aug;54(4):543-51. Epub 2007 Jun 13.

39.

Development of a specific inhibitor for the placental protease, cathepsin P.

Hassanein M, Xue F, Seto CT, Mason RW.

Arch Biochem Biophys. 2007 Aug 15;464(2):288-94. Epub 2007 May 7.

PMID:
17531191
40.

The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys.

Chang SW, Reddy V, Pereira T, Dean BJ, Xia YQ, Seto C, Franklin RB, Karanam BV.

Xenobiotica. 2007 May;37(5):514-33.

PMID:
17523054
41.

Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.

Lévesque JF, Day SH, Chauret N, Seto C, Trimble L, Bateman KP, Silva JM, Berthelette C, Lachance N, Boyd M, Li L, Sturino CF, Wang Z, Zamboni R, Young RN, Nicoll-Griffith DA.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3038-43. Epub 2007 Mar 23.

PMID:
17418572
42.

Anastomotic leakage is associated with poor long-term outcome in patients after curative colorectal resection for malignancy.

Law WL, Choi HK, Lee YM, Ho JW, Seto CL.

J Gastrointest Surg. 2007 Jan;11(1):8-15.

PMID:
17390180
43.

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM.

J Med Chem. 2007 Feb 22;50(4):794-806.

PMID:
17300164
44.

Early outcomes of surgery for small bowel obstruction: analysis of risk factors.

Lo OS, Law WL, Choi HK, Lee YM, Ho JW, Seto CL.

Langenbecks Arch Surg. 2007 Mar;392(2):173-8. Epub 2007 Jan 19.

PMID:
17235588
45.

Impact of laparoscopic resection for colorectal cancer on operative outcomes and survival.

Law WL, Lee YM, Choi HK, Seto CL, Ho JW.

Ann Surg. 2007 Jan;245(1):1-7.

46.

In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.

Nicoll-Griffith DA, Seto C, Aubin Y, Lévesque JF, Chauret N, Day S, Silva JM, Trimble LA, Truchon JF, Berthelette C, Lachance N, Wang Z, Sturino C, Braun M, Zamboni R, Young RN.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):301-4. Epub 2006 Oct 25.

PMID:
17095220
47.

A two stage click-based library of protein tyrosine phosphatase inhibitors.

Xie J, Seto CT.

Bioorg Med Chem. 2007 Jan 1;15(1):458-73. Epub 2006 Oct 12.

48.
49.

Enantioselective addition of vinylzinc reagents to 3,4-dihydroisoquinoline N-oxide.

Wang S, Seto CT.

Org Lett. 2006 Aug 31;8(18):3979-82.

PMID:
16928053
50.

Supplemental Content

Support Center